Late-onset <i>NPM1</i> mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib
Sonia Jaramillo,
Michael Scherer,
Chelsea Szu-Tu,
Sergi Beneyto-Calabuig,
Carsten Müller-Tidow,
Richard F. Schlenk,
Michael Hundemer,
Lars Velten,
Caroline Pabst
Affiliations
Sonia Jaramillo
Department of Internal Medicine V, Heidelberg University Hospital
Michael Scherer
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona
Chelsea Szu-Tu
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona
Sergi Beneyto-Calabuig
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona
Carsten Müller-Tidow
Department of Internal Medicine V, Heidelberg University Hospital, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg
Richard F. Schlenk
Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center
Michael Hundemer
Department of Internal Medicine V, Heidelberg University Hospital
Lars Velten
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona
Caroline Pabst
Department of Internal Medicine V, Heidelberg University Hospital, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg
